Definium Therapeutics
The Director of Tax at Definium Therapeutics will develop and execute the company's tax strategy as it transitions from a development-stage to a commercial-stage biopharmaceutical company. This role serves as the primary internal tax resource, overseeing tax accounting, planning, compliance, and building infrastructure to support commercial operations. The position requires a strategic yet hands-on approach to manage tax readiness, external advisors, and cross-functional partnerships.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company harnessing the therapeutic potential of psychedelic medicine to develop treatments for psychiatric conditions including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Its lead programs include DT120 ODT, a proprietary formulation of lysergide (LSD) D-tartrate, and DT402, the R-enantiomer of MDMA targeting core symptoms of autism spectrum disorder. The company is guided by precision science and evidence-based development to redefine mental healthcare.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.